ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 750 participants.
Also called NCT06716021
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 750 participants
- Registry
-
NCT06716021
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Netherlands
- Registry status
- Recruiting
Technical summary
Registry record NCT06716021. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-20 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3
- Acronym
- ReVeRA-301
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Etripamil
- Lead sponsor
- Milestone Pharmaceuticals Inc.
Record details
- Record id
cardio:ct-nct06716021- Content hash
0ec32defd44123206e1a2302a3eddfa0455626c0bdc9c6c40438a147d60186e2